Children aged 10 months to 5 years with two or more wheeze episodes were allocated to either a 5/5 or 5/x + x/x ALOX5 promoter genotype stratum , then randomly assigned ( 1:1 ) via a permuted block schedule ( size ten ) , to receive intermittent montelukast or placebo given by parents at each wheeze episode over a 12 month period .